FIRST trial results of Revlimid plus dexamethasone for newly diagnosed myeloma patients published

Data from the FIRST trial, an open-label Phase III randomised study have shown that continuous Revlimid and dexamethasone (Rd) treatment for newly diagnosed transplant ineligible myeloma patients significantly improved PFS and overall survival compared to fixed length Rd or standard melphalan, prednisone and thalidomide (MPT) treatment. Based on the results of this trial, Celgene, the…

Details

Continuous treatment improves outcomes in newly diagnosed transplant-ineligible myeloma patients

Results from the Phase III FIRST (MM-020/IFM 07-01) trial, published in the New England Journal of Medicine, have demonstrated that continuous treatment with Revlimid┬« and low-dose dexamethasone, given until disease progression, improved progression-free survival and overall survival in newly diagnosed transplant-ineligible myeloma patients compared to those receiving a fixed period (72 weeks) of the same…

Details